Ovarian cancer in younger women
Ovarian cancer in young women is less common. However, if you are a young woman with ovarian cancer and would still like to have children, our doctors will discuss your best options to preserve your fertility. If the cancer is at an early stage (stage
I or II), one ovary (unilateral oophorectomy) and one fallopian tube (unilateral salpingectomy) may be removed (when possible) to preserve reproductive functions. In later stages where the cancer has spread, broader surgery may be necessary. At any
stage, we suggest discussing your fertility options and concerns with the dedicated
fertility and reproductive specialists at DF/BWCC. For example, you may consider egg harvesting or embryo (egg)
freezing until treatment concludes.
Surgery takes place in the operating suites at Brigham and Women's Hospital, whose gynecology program is widely recognized as one of the best in the country. Post-surgical care and other inpatient care are provided by the DF/BWCC team either at Brigham
and Women's Hospital or at Dana-Farber's Inpatient Hospital located within Brigham and Women's Hospital.
post-operative guidelines for gynecologic surgery.
Learn about strategies and tips for
recovering from your hysterectomy.
Medical oncologists are medical doctors who study and treat cancers. Medical oncologists at DF/BWCC offer the most effective therapies possible, while helping you maintain your quality of life during treatment. Chemotherapy is provided at Dana-Farber's
Yawkey Center for Cancer Care, one of the most advanced outpatient cancer centers in the country — designed by patients, for patients.
Chemotherapy for ovarian cancer may be administered at any stage, but it is usually given at the later stages of the disease. In general, chemotherapy drugs are administered after surgery to eliminate remaining cancer cells, or to keep them from returning.
However, there are times when chemotherapy will be given before surgery to make the tumor easier to remove.
- One type of chemotherapy used to treat regions of the female body is intraperitoneal (IP) chemotherapy. In this process, chemotherapy drugs are injected directly through a thin tube that is placed during the initial surgery into the peritoneal
cavity (the space that contains the organs of the abdomen). This type of chemotherapy is primarily given to stage III ovarian cancer patients in conjunction with chemotherapy drugs given intravenously.
Throughout your treatment, your medical oncologist will work closely with your team of nurses, nutritionists, and social workers to minimize the toxicities and side effects of chemotherapy, maintain your quality of life, and optimize your results. We
encourage you to be actively involved in the decision-making process when it comes to choices about chemotherapy treatment.
Heated Chemotherapy in the Abdomen
Dana-Farber/Brigham and Women’s Cancer Center offers an advanced treatment for ovarian cancer that has already spread within the abdominal cavity. While the combination of intravenous chemotherapy and surgery is the best treatment approach for many women, recent studies have shown that a significant improvement in survival can be seen for select patients receiving hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of surgery. HIPEC delivers chemotherapy directly to cancer cells in the abdomen, so it is well-suited to the treatment of ovarian cancer.
Heating the chemotherapy improves absorption of chemotherapy and directly destroys cancer cells. At the completion of the surgery, the chemotherapy is removed from the abdomen. Of equal importance, recent studies have also shown that adding HIPEC to a patient’s treatment doesn’t increase patient side-effects or complications. HIPEC is for select patients with advanced stage ovarian cancer and we encourage patients to discuss treatment options with their cancer team.
Radiation therapy is a cancer treatment that uses high-energy X-rays or other types of radiation to eliminate cancer cells or stop cancer growth. Radiation therapy for ovarian cancer is given by our experienced team of radiation oncologists. They are
pioneers in the field, regularly setting standards nationwide for treatment and safety.
Radiation therapy is used to treat select cases of ovarian cancer. While most ovarian cancer patients are not treated with radiation therapy, it may be used for patients with certain types of ovarian cancer, those who have isolated and/or minimal recurrence,
or to control symptoms such as pain. In rare or recurrent cases, these radiation treatments may be performed:
- 3D imaging radiation therapy called intensity-modulated radiation therapy (IMRT). IMRT uses computer images to find and target the cancerous tumor. Radiation is externally delivered and aimed at the tumor, firing thin radiation beams from different
angles. This reduces the damage to the surrounding healthy tissue.
interstitial brachytherapy, radioactive material is directly implanted in or near the tumor via a tiny needle, wire, or other device. Our radiation oncologists at DF/BWCC are
among a limited few in the nation to deliver this type of radiation with image-guided techniques. Occasionally, cylinder brachytherapy, a type of radiation therapy delivered to the vagina, will be performed on patients after surgery.
Revolutionary imaging therapies
For rare cases of ovarian cancer that require complex imaging treatment, you will be cared for in an innovative operating and research environment developed at Brigham and Women's Hospital (BWH) in 2011. Called the
Advanced Multimodality Image Guided Operating (AMIGO) Suite, our team of surgeons, interventional radiologists, imaging physicists, computer scientists,
biomedical engineers, nurses, and technologists use the latest imaging tools to develop and deliver the safest, state-of-the-art therapies. The AMIGO suite is unique, as it combines PET/CT, MRI, and OR technologies in one operating room. BWH is
one of the few hospitals in the United States to operate an AMIGO suite.
Clinical trials for ovarian cancer
DF/BWCC offers one of the largest and most active clinical trial programs available, including
clinical trials for women with ovarian cancer. The clinical trials conducted at DF/BWCC have had a meaningful impact on the type of care administered worldwide.
Clinical trials are available for nearly every stage of ovarian cancer. However, for women with advanced or recurrent cases of ovarian cancer, taking part in a clinical trial may be the best treatment option. If you qualify for a clinical trial, your
doctor will carefully discuss all options and the best time to begin a trial.
Clinical trials are part of the cancer research process; they are safe and regulated research studies to determine if new cancer treatments are effective, or better than a current plan. Not only can trials lead to new discoveries and improve cancer care,
but they can have meaningful anti-cancer benefits.
Clinical trials may include biologic therapies, or treatments that use the patient's immune system to fight the cancer (immunotherapy or biotherapy). Trials also include targeted therapy or therapies using drugs to identify and attack the specific ovarian
Find out more about
clinical trials at DF/BWCC. Detailed information about clinical trials is available from the
NCI website. For nationally run clinical trials, please visit
Clinical trial studies are underway at DF/BWCC using new drugs called PARP (poly-ADP-ribose polymerase) inhibitors, some of the more promising drugs for women with ovarian cancer, especially recurrent cases. PARP inhibitors are agents that do not allow
the repair of DNA to occur. They are particularly successful in women with a subtype of ovarian cancer called high-grade serous cancer and those women with BRCA mutations (germline mutations inherited from the parents). PARP inhibitors are now being
combined with other targeted biological therapies to improve the use of single agent PARP inhibitors. For some women with high-grade serous tumors and BRCA mutations, the response rates from PARP inhibitors have been higher than would be expected
from traditional chemotherapy. Various PARP inhibitors are available on clinical studies.
Read about research findings for
high-grade serous ovarian cancer.
Questions to ask your doctor about clinical trials
If your doctor suggests a clinical trial as part of your cancer treatment, you may have questions before you get started. Review some
commonly asked questions about clinical trials and discuss them with your doctor.